Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Author Correction: Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.

Lopeman RC, Harrison J, Rathbone DL, Desai M, Lambert PA, Cox JAG.

Sci Rep. 2020 Mar 6;10(1):4540. doi: 10.1038/s41598-020-61546-6.

2.

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus.

Lopeman RC, Harrison J, Rathbone DL, Desai M, Lambert PA, Cox JAG.

Sci Rep. 2020 Jan 27;10(1):928. doi: 10.1038/s41598-020-57844-8. Erratum in: Sci Rep. 2020 Mar 6;10(1):4540.

3.

Dissecting the Antimicrobial Composition of Honey.

Nolan VC, Harrison J, Cox JAG.

Antibiotics (Basel). 2019 Dec 5;8(4). pii: E251. doi: 10.3390/antibiotics8040251. Review.

4.

Changing the Rules of TB-Drug Discovery.

Harrison J, Cox JAG.

J Med Chem. 2019 Dec 12;62(23):10583-10585. doi: 10.1021/acs.jmedchem.9b01716. Epub 2019 Oct 30.

PMID:
31664826
5.

Mycobacterium abscessus: Environmental Bacterium Turned Clinical Nightmare.

Lopeman RC, Harrison J, Desai M, Cox JAG.

Microorganisms. 2019 Mar 22;7(3). pii: E90. doi: 10.3390/microorganisms7030090. Review.

6.

Crystal structure of Mycobacterium tuberculosis FadB2 implicated in mycobacterial β-oxidation.

Cox JAG, Taylor RC, Brown AK, Attoe S, Besra GS, Fütterer K.

Acta Crystallogr D Struct Biol. 2019 Jan 1;75(Pt 1):101-108. doi: 10.1107/S2059798318017242. Epub 2019 Jan 8.

7.

Modelling a Silent Epidemic: A Review of the In Vitro Models of Latent Tuberculosis.

Gibson SER, Harrison J, Cox JAG.

Pathogens. 2018 Nov 15;7(4). pii: E88. doi: 10.3390/pathogens7040088. Review.

8.

Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets.

Trofimov V, Kicka S, Mucaria S, Hanna N, Ramon-Olayo F, Del Peral LV, Lelièvre J, Ballell L, Scapozza L, Besra GS, Cox JAG, Soldati T.

Sci Rep. 2018 Mar 2;8(1):3939. doi: 10.1038/s41598-018-22228-6.

9.

Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface.

Abrahams KA, Cox JAG, Fütterer K, Rullas J, Ortega-Muro F, Loman NJ, Moynihan PJ, Pérez-Herrán E, Jiménez E, Esquivias J, Barros D, Ballell L, Alemparte C, Besra GS.

Sci Rep. 2017 Aug 25;7(1):9430. doi: 10.1038/s41598-017-09642-y.

10.

Drug development: The cell wall as a drug target.

Cox JA.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S156. doi: 10.1016/j.ijmyco.2016.09.012. Epub 2016 Oct 18. No abstract available.

11.

The 'Antibiotic Apocalypse' - Scaremongering or Scientific Reporting?

Cox JAG, Worthington T.

Trends Microbiol. 2017 Mar;25(3):167-169. doi: 10.1016/j.tim.2016.11.016. Epub 2016 Dec 23.

PMID:
28024669
12.

Novel inhibitors of Mycobacterium tuberculosis GuaB2 identified by a target based high-throughput phenotypic screen.

Cox JA, Mugumbate G, Del Peral LV, Jankute M, Abrahams KA, Jervis P, Jackenkroll S, Perez A, Alemparte C, Esquivias J, Lelièvre J, Ramon F, Barros D, Ballell L, Besra GS.

Sci Rep. 2016 Dec 16;6:38986. doi: 10.1038/srep38986.

13.

Identification of KasA as the cellular target of an anti-tubercular scaffold.

Abrahams KA, Chung CW, Ghidelli-Disse S, Rullas J, Rebollo-López MJ, Gurcha SS, Cox JA, Mendoza A, Jiménez-Navarro E, Martínez-Martínez MS, Neu M, Shillings A, Homes P, Argyrou A, Casanueva R, Loman NJ, Moynihan PJ, Lelièvre J, Selenski C, Axtman M, Kremer L, Bantscheff M, Angulo-Barturen I, Izquierdo MC, Cammack NC, Drewes G, Ballell L, Barros D, Besra GS, Bates RH.

Nat Commun. 2016 Sep 1;7:12581. doi: 10.1038/ncomms12581.

14.

THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria.

Cox JA, Abrahams KA, Alemparte C, Ghidelli-Disse S, Rullas J, Angulo-Barturen I, Singh A, Gurcha SS, Nataraj V, Bethell S, Remuiñán MJ, Encinas L, Jervis PJ, Cammack NC, Bhatt A, Kruse U, Bantscheff M, Fütterer K, Barros D, Ballell L, Drewes G, Besra GS.

Nat Microbiol. 2016 Jan 18;1:15006. doi: 10.1038/nmicrobiol.2015.6.

PMID:
27571973
15.

Assembly of the Mycobacterial Cell Wall.

Jankute M, Cox JA, Harrison J, Besra GS.

Annu Rev Microbiol. 2015;69:405-23. doi: 10.1146/annurev-micro-091014-104121. Review.

PMID:
26488279
16.

Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation.

Mugumbate G, Abrahams KA, Cox JA, Papadatos G, van Westen G, Lelièvre J, Calus ST, Loman NJ, Ballell L, Barros D, Overington JP, Besra GS.

PLoS One. 2015 Mar 23;10(3):e0121492. doi: 10.1371/journal.pone.0121492. eCollection 2015.

17.

Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target.

Gurcha SS, Usha V, Cox JA, Fütterer K, Abrahams KA, Bhatt A, Alderwick LJ, Reynolds RC, Loman NJ, Nataraj V, Alemparte C, Barros D, Lloyd AJ, Ballell L, Hobrath JV, Besra GS.

PLoS One. 2014 Nov 19;9(11):e113568. doi: 10.1371/journal.pone.0113568. eCollection 2014.

18.

Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB.

Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Fernández R, Alemparte C, Remuiñán MJ, Barros D, Ballell L, Besra GS.

PLoS One. 2012;7(12):e52951. doi: 10.1371/journal.pone.0052951. Epub 2012 Dec 31.

Supplemental Content

Loading ...
Support Center